Vanda Approves Key Proposals at Annual Meeting

The latest announcement is out from Vanda ( (VNDA) ).

At the 2025 annual meeting of stockholders held on June 5, Vanda Pharmaceuticals Inc. presented four proposals, all of which were approved. These included the election of two directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, an advisory vote on executive compensation, and an amendment to the 2016 Equity Incentive Plan to increase share issuance and eliminate its term. Approximately 79% of the company’s common stock was represented at the meeting.

The most recent analyst rating on (VNDA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.

Spark’s Take on VNDA Stock

According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.

Vanda Pharmaceuticals’ overall stock score reflects significant financial challenges, weak technical indicators, and unattractive valuation. Despite potential growth from new products and corporate events, operational inefficiencies and regulatory challenges weigh heavily on the stock.

To see Spark’s full report on VNDA stock, click here.

More about Vanda

Vanda Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of products for the treatment of central nervous system disorders.

Average Trading Volume: 572,235

Technical Sentiment Signal: Sell

Current Market Cap: $258.7M

Learn more about VNDA stock on TipRanks’ Stock Analysis page.